We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Sertraline for Preventing Mood Disorders Following Traumatic Brain Injury A Randomized Clinical Trial ONLINE FIRST

Ricardo E. Jorge, MD1; Laura Acion, PhD1,2,3; Debora I. Burin, PhD4; Robert G. Robinson, MD5
[+] Author Affiliations
1Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, Texas
2Iowa Consortium for Substance Abuse Research and Evaluation, University of Iowa, Iowa City
3Instituto de Cálculo, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires–Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
4Facultad de Psicología, Universidad de Buenos Aires–Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina
5Department of Psychiatry, University of Iowa, Iowa City
JAMA Psychiatry. Published online September 14, 2016. doi:10.1001/jamapsychiatry.2016.2189
Text Size: A A A
Published online

Importance  Prevention is more effective than treatment to decrease the burden of significant medical conditions such as depressive disorders, a major cause of disability worldwide. Traumatic brain injury (TBI) is a candidate for selective strategies to prevent depression given the incidence, prevalence, and functional effect of depression that occurs after TBI.

Objective  To assess the efficacy of sertraline treatment in preventing depressive disorders following TBI.

Design, Setting, and Participants  A double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted at a university hospital from July 3, 2008, to September 17, 2012, with 24 weeks of follow-up. A consecutive sample of 534 patients aged 18 to 85 years, hospitalized for mild, moderate, or severe TBI, was eligible for the study. Ninety-four patients consented to participate and were randomized (46 to placebo and 48 to sertraline), of whom 79 (84%) completed the study. Intention-to-treat data analysis was conducted from July 1, 2014, to December 31, 2015.

Interventions  Placebo or sertraline, 100 mg/d, for 24 weeks or until development of a mood disorder.

Main Outcomes and Measures  Time to onset of depressive disorders, as defined by the DSM-IV, associated with TBI.

Results  Of the 94 patients in the study (38 female and 56 male; 92 white), the number needed to treat to prevent depression after TBI at 24 weeks was 5.9 (95% CI, 3.1-71.1; χ2 = 4.6; P = .03) for sertraline treatment vs placebo. The influence of sertraline in the course of neuropsychological variables was not detected. The intervention was well tolerated, and adverse effects were mild in both the sertraline and placebo groups.

Conclusions and Relevance  Sertraline appears to be efficacious to prevent the onset of depressive disorders following TBI. Future studies should replicate these findings in a large sample of patients with TBI and depict their long-term physical, cognitive, behavioral, and functional outcomes.

Trial Registration  clinicaltrials.gov Identifier: NCT00704379

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Figure 1.
Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Risk Comparison of Onset of Mood Disorder for Patients Receiving Sertraline or Placebo

Tick marks show censored observations. NNT indicates number needed to treat; NNTB, number needed to treat to benefit; and NNTH, number needed to treat to harm.

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Care at the Close of Life: Evidence and Experience
Diagnosing Brain Death